Skip to main content

Knocked Sensiparless–high deductibles and co-insurances hitting patients and providers hard

April 2018, Nephrology Times, by Rick Collins Chief Operating Officer Sceptre Management Solutions, Inc.

Patients and providers using Sensipar® (cinacalcet) and Parsabiv™ (etelcalcetide) are experiencing significantly increased financial liability due to inconsistent coverage of the drugs by payers and the dramatic increase in the coinsurance amount assigned by Medicare Part B. The biggest causes of potential lost reimbursement for providers are Medicare … Read More »